Need to Know: Here’s one analyst’s take on the coronavirus drugs for today and the future
Before touching on the latest developments in tackling the economic effects of coronavirus, it is worth discussing the scientific efforts.
Analysts at Bernstein Research, in a comprehensive note, discussed what approaches are worth keeping an eye on.
For treating victims, existing drugs in development are “clearly the best best,” they say — this includes antivirals, immunomodulatory drugs, antibodies, ACE2 targets, IPF therapeutics, and plasma therapies. “The focus here is saving lives and reducing symptoms but it is not the solution,” said the analysts led by Wimal Kapadia. Companies making these include Gilead
“COVID-19 is a very different beast to MERS/SARS and so expect focus on development until we have a vaccine solution. This is even more of a necessity given the debate around ‘reinfection’ which could be COVID-19 specific,” say the analysts. They don’t think that will be quick — a vaccine approval by the end of 2021 is a possibility. And yes — the analysts think a COVID-19 vaccine would be profitable.
The Federal Reserve late on Tuesday unveiled its latest measure to keep credit flowing, a so-called primary dealer facility which allows a variety of securities, including stocks, to be used as collateral for supercheap borrowing. The European Central Bank issued a rare statement rejecting the comments of one of its members, Austria’s Robert Holzmann, after he had said the central bank was out of tools to help the economy.
Treasury Secretary Steven Mnuchin told reporters he was discussing a package worth $1 trillion, including direct payments to Americans, and reportedly warned Senate Republicans the unemployment rate could reach 20% without assistance.
Former Vice President Joe Biden extended his delegate lead in the Democratic presidential primary over Sen. Bernie Sanders, with wins in Arizona, Florida and Illinois.
Retail investors have not capitulated. Analysts at Barclays estimate that total U.S. fund outflows (ETFs and mutual funds) for the past three weeks are around $25 billion, which are much smaller than past sell-offs which have been in the range of $40 billion to $50 billion.
Oprah Winfrey says, despite her name trending on Twitter, she is a free bird.
Just got a phone call that my name is trending. And being trolled for some awful FAKE thing. It’s NOT TRUE. Haven’t been raided, or arrested. Just sanitizing and self distancing with the rest of the world. Stay safe everybody.🙏🏾
Need to Know starts early and is updated until the opening bell, but sign up here to get it delivered once to your email box. Be sure to check the Need to Know item. The emailed version will be sent out at about 7:30 a.m. Eastern.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.